基石科技控股(08391.HK)完成配售800萬股 淨籌494萬港元
格隆匯12月6日丨基石科技控股(08391.HK)宣佈,認購協議的所有先決條件已獲達成,而認購事項已於2021年12月6日完成。於完成後,公司已根據一般授權按認購價每股認購股份0.62港元向認購人發行及配發合共800萬股認購股份,相當於公司於公佈日期經認購事項擴大的已發行股本約1.32%。
認購事項所得款項總額約為496萬港元,而經扣除認購事項附帶的所有相關開支後,認購事項產生的所得款項淨額約為494萬港元,有關款項擬用作公司的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.